MetLife Form 144 Discloses Proposed 221-Share Sale via Bernstein
Rhea-AI Filing Summary
MetLife, Inc. (MET) filed a Form 144 reporting a proposed sale of 221 shares of common stock through Bernstein Institutional Services LLC with an aggregate market value of $17,474.47. The notice lists the company’s outstanding shares as 665,026,054 and an approximate sale date of 09/19/2025. The shares were originally acquired on 05/29/2015 in a purchase from Goldman Sachs with cash payment on 06/03/2015. The filing also discloses several recent sales by MetLife-related accounts between 06/20/2025 and 07/31/2025 totaling multiple transactions and varying gross proceeds.
Positive
- None.
Negative
- None.
Insights
TL;DR: Small scheduled insider sale; disclosed per Rule 144 with recent related-account sales noted; appears immaterial to market capitalization.
The form documents a proposed sale of 221 shares valued at $17,474.47 against total outstanding shares of 665,026,054, indicating the transaction is extremely small relative to the company’s float. The filer reports acquisition details (05/29/2015 purchase from Goldman Sachs) and cash payment on 06/03/2015, meeting Rule 144 disclosure requirements. The filing also lists several recent sales by MetLife-managed accounts with specified quantities and gross proceeds, which provide context but do not, by themselves, indicate material shifts in ownership or control.
TL;DR: Documentation complies with Rule 144 disclosure norms; no material adverse facts presented in the notice.
The submission includes broker details, acquisition history, payment method, and recent aggregated sales by MetLife-related accounts. The filer’s attestation that they are unaware of undisclosed material adverse information is present. From a compliance perspective, the form contains the expected elements to satisfy Rule 144 reporting for an intended sale and records previous transactions relevant to aggregation rules.